These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 2494830

  • 1. Characterization of the fibrinolytic state by measuring stable cross-linked fibrin degradation products in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
    Okajima K, Koga S, Okabe H, Inoue M, Takatsuki K.
    Acta Haematol; 1989; 81(1):15-8. PubMed ID: 2494830
    [Abstract] [Full Text] [Related]

  • 2. [Studies on the fragments of FDP in 3 patients with DIC associated with acute promyelocytic leukemia].
    Okumura N, Furuwatari C, Ishikawa S, Furihata K, Katsuyama T, Kanai M, Nakahata T, Saitoh H.
    Rinsho Byori; 1993 Jun; 41(6):719-25. PubMed ID: 8361040
    [Abstract] [Full Text] [Related]

  • 3. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation.
    Takahashi H, Tatewaki W, Wada K, Niwano H, Shibata A.
    Thromb Haemost; 1990 Jun 28; 63(3):340-4. PubMed ID: 2402738
    [Abstract] [Full Text] [Related]

  • 4. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.
    Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, Degos L.
    Leukemia; 1993 Jan 28; 7(1):2-9. PubMed ID: 8418375
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Intravascular coagulation in acute promyelocytic leukemia: analysis of coagulation and fibrinolysis parameters].
    Chuecas F, Loredo E, Muñoz B, Alfaro J, Grebe G, Lira P.
    Rev Med Chil; 1991 Sep 28; 119(9):984-9. PubMed ID: 1845106
    [Abstract] [Full Text] [Related]

  • 7. Elastase mediated fibrinolysis in acute promyelocytic leukemia.
    Oudijk EJ, Nieuwenhuis HK, Bos R, Fijnheer R.
    Thromb Haemost; 2000 Jun 28; 83(6):906-8. PubMed ID: 10896247
    [Abstract] [Full Text] [Related]

  • 8. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.
    Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T.
    Blood Coagul Fibrinolysis; 1994 Oct 28; 5(5):829-32. PubMed ID: 7865691
    [Abstract] [Full Text] [Related]

  • 9. [Progress in diagnosis of disseminated intravascular coagulation (DIC)--diagnostic criteria of DIC].
    Koyama T, Aoki N.
    Nihon Rinsho; 1993 Jan 28; 51(1):43-9. PubMed ID: 8433527
    [Abstract] [Full Text] [Related]

  • 10. [Coagulation and fibrinolysis parameters in disseminated intravascular coagulation (DIC)].
    Nakagawa T, Saito H, Watanabe Y, Sato M, Murakawa E.
    Rinsho Byori; 1991 Mar 28; 39(3):309-14. PubMed ID: 1828842
    [Abstract] [Full Text] [Related]

  • 11. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
    Gando S, Hayakawa M, Sawamura A, Hoshino H, Oshiro A, Kubota N, Jesmin S.
    Thromb Res; 2007 Mar 28; 121(1):67-73. PubMed ID: 17397908
    [Abstract] [Full Text] [Related]

  • 12. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T.
    Am J Hematol; 2003 Jan 28; 72(1):1-7. PubMed ID: 12508260
    [Abstract] [Full Text] [Related]

  • 13. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
    Imoto K, Yasumuro Y, Taki M, Suzuki N, Tanabe H, Ichikawa Y.
    Rinsho Byori; 2001 Mar 28; 49(3):283-9. PubMed ID: 11307330
    [Abstract] [Full Text] [Related]

  • 14. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T, Gando S, Mizugaki A, Yanagida Y, Jesmin S, Yokota H, Ieko M.
    Thromb Res; 2013 Jul 28; 132(1):e64-9. PubMed ID: 23726093
    [Abstract] [Full Text] [Related]

  • 15. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N, Furuwatari C, Ishikawa S, Furihata K, Katsuyama T, Kanai M, Nakahata T, Saitoh H.
    Rinsho Byori; 1992 Jul 28; 40(7):789-94. PubMed ID: 1507499
    [Abstract] [Full Text] [Related]

  • 16. Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
    Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K.
    Am J Hematol; 1996 Mar 28; 51(3):186-91. PubMed ID: 8619398
    [Abstract] [Full Text] [Related]

  • 17. [Studies on the fragments of FDP in 4 patients with DIC].
    Okumura N, Furuwatari C, Ishikawa S, Furihata K, Katsuyama T, Kanai M, Nakahata T, Saitoh H.
    Rinsho Byori; 1992 Oct 28; 40(10):1089-95. PubMed ID: 1307614
    [Abstract] [Full Text] [Related]

  • 18. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
    Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H.
    Haemostasis; 1992 Oct 28; 22(4):179-86. PubMed ID: 1468720
    [Abstract] [Full Text] [Related]

  • 19. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders.
    Williams EC.
    Arch Intern Med; 1989 Aug 28; 149(8):1769-72. PubMed ID: 2475079
    [Abstract] [Full Text] [Related]

  • 20. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation.
    Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A.
    Am J Hematol; 1988 Jul 28; 28(3):162-6. PubMed ID: 2457307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.